TRECONDI

This brand name is authorized in Austria, Croatia, Estonia, Finland, France, Ireland, Italy, Lithuania, Netherlands, Poland, Spain, UK.

Active ingredients

The drug TRECONDI contains one active pharmaceutical ingredient (API):

1	Treosulfan UNII CO61ER3EPI - TREOSULFAN
	Treosulfan is a prodrug of a bifunctional alkylating agent with cytotoxic activity to haematopoietic precursor cells. The activity of treosulfan is due to the spontaneous conversion into a mono-epoxide intermediate and L-diepoxybutan. Treosulfan has a broad antineoplastic and antileukaemic activity.
	Read more about Treosulfan

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
TRECONDI Powder for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01AB02	Treosulfan	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01A Alkylating agents → L01AB Alkyl sulfonates
Discover more medicines within L01AB02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1798229, 1798230, 1798241, 1798252
ES	Centro de información online de medicamentos de la AEMPS	1181351003
FI	Lääkealan turvallisuus- ja kehittämiskeskus	428636, 477431
FR	Base de données publique des médicaments	68966390, 69719293
GB	Medicines & Healthcare Products Regulatory Agency	382423, 382425
IT	Agenzia del Farmaco	048082010, 048082022, 048082034, 048082046
LT	Valstybinė vaistų kontrolės tarnyba	1088080, 1088081, 1088082, 1088083
NL	Z-Index G-Standaard, PRK	94765, 94773
PL	Rejestru Produktów Leczniczych	100423571, 100423594